Calliditas Therapeutics AB (publ) (CALTX.ST)

SEK 208.0

(0.87%)

Market Cap (In SEK)

11.23 Billion

Revenue (In SEK)

1.2 Billion

Net Income (In SEK)

-466.18 Million

Avg. Volume

120.75 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
80.8-208.8
PE
-
EPS
-
Beta Value
1.457
ISIN
SE0010441584
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Renee Aguiar-Lucander
Employee Count
-
Website
https://www.calliditas.se
Ipo Date
2018-06-29
Details
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.